Nicolet Advisory Services’s VistaGen Therapeutics VTGN Stock Holding History

Nicolet Advisory Services’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-333	Closed	-$1K	–	246
2022 Q3	$1K	Hold	333	–	–	﹤0.01%	193
2022 Q2	$10K	Hold	333	–	–	﹤0.01%	186
2022 Q1	$14K	Hold	333	–	–	﹤0.01%	200
2021 Q4	$20K	Hold	333	–	–	﹤0.01%	208
2021 Q3	$27K	Hold	333	–	–	﹤0.01%	202
2021 Q2	$32K	Hold	333	–	–	﹤0.01%	189
2021 Q1	$21K	Hold	333	–	–	﹤0.01%	175
2020 Q4	$19K	Hold	333	–	–	﹤0.01%	173
2020 Q3	$7K	Buy	+333	New	+$6.89K	﹤0.01%	174

Other funds holding VTGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Nicolet Advisory Services's VTGN Position: Q4 2022 in Review

Nicolet Advisory Services sold out of VistaGen Therapeutics (VTGN) in Q4 2022, closing a stake of 333 shares — an estimated $1K sold.

Nicolet Advisory Services first reported a position in VTGN in Q3 2020 and held it in 9 quarters. The position peaked at $32K in Q2 2021. 85 funds tracked by Wall St. Rank hold VTGN as of Q4 2022.

Nicolet Advisory Services reported no remaining VistaGen Therapeutics position as of Q4 2022 after selling out during the quarter.
Nicolet Advisory Services sold 333 VistaGen Therapeutics shares in Q4 2022, an estimated $1K.
Nicolet Advisory Services first reported a position in VistaGen Therapeutics in Q3 2020 and held it in 9 quarters.
Nicolet Advisory Services's VistaGen Therapeutics position peaked at $32K in Q2 2021.
85 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q4 2022.

Based on Nicolet Advisory Services's 13F filing for Q4 2022, filed 9 Feb 2023.